assessing the impact of atezolizumab in nsclc
Published 2 years ago • 1.1K plays • Length 1:21Download video MP4
Download video MP3
Similar videos
-
1:41
adjuvant atezolizumab in nsclc
-
1:18
lung cancer: the impact of immunotherapy
-
4:18
impower110: atezolizumab vs chemo in pd-l1–selected nsclc
-
5:06
subgroup analysis of oak trial data supports use of atezolizumab in patients with nsclc
-
2:59
lcmc3 primary analysis: neoadjuvant atezolizumab in nsclc
-
3:17
impower010: os results of atezolizumab vs best supportive care in resected nsclc
-
3:07
neoadjuvant atezolizumab in nsclc
-
15:25
targeted therapies: the future of non-small cell lung cancer (nsclc) treatment?
-
5:02
evaluating the lipi for first line immunotherapy in nsclc
-
2:03
t-cell dynamics in response to neoadjuvant atezolizumab in early nsclc
-
3:30
princeps study: atezolizumab for resectable nsclc
-
1:31
impower150: efficacy outcomes of atezolizumab addition in pre-treated egfr-mutated nsclc
-
2:44
disease-free survival in impower010 trial: adjuvant atezolizumab in nsclc
-
1:03
sangeetha palakurthi on fda approval of atezolizumab in nsclc
-
3:11
impower150: atezolizumab, chemotherapy and bevacizumab for nsclc
-
0:36
dr. camidge on the fda approval of pembrolizumab for squamous nsclc
-
1:50
pd-l1 agents in the treatment of nsclc
-
1:39
lcmc3: adjuvant and neoadjuvant atezolizumab in early-stage ncslc
-
3:26
the impact of novel nsclc immunotherapies